Detalles de la búsqueda
1.
Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Solid Organ Transplant Recipients.
J Infect Dis;
2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38513368
2.
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
J Infect Dis;
227(2): 268-277, 2023 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35776140
3.
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Lancet;
392(10143): 232-243, 2018 07 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30047376
4.
Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value.
AIDS Behav;
22(4): 1165-1173, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29090394
5.
Using Digital Technologies in Clinical HIV Research: Real-World Applications and Considerations for Future Work.
J Med Internet Res;
19(7): e274, 2017 07 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-28760729
6.
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
AIDS Behav;
19(5): 794-801, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25432877
7.
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Lancet Infect Dis;
2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38518789
8.
High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya.
AIDS Behav;
17(6): 2162-72, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23080358
9.
Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
Vaccine;
41(38): 5535-5544, 2023 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37516574
10.
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.
PLoS Pathog;
6(8): e1001028, 2010 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-20700449
11.
Developing standards of care for HIV prevention research in developing countries -- a case study of 10 research centers in Eastern and Southern Africa.
AIDS Care;
24(10): 1277-89, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22452384
12.
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.
Vaccine;
40(34): 5050-5059, 2022 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35868948
13.
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.
Trials;
23(1): 513, 2022 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35725488
14.
Development and deployment of COVID-19 vaccines for those most vulnerable.
Sci Transl Med;
13(579)2021 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33536277
15.
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
Nat Med;
27(10): 1718-1724, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34621054
16.
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
J Virol;
83(14): 7337-48, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19439467
17.
High prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections among HIV-1 negative men who have sex with men in coastal Kenya.
Sex Transm Infect;
86(6): 440-1, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20656722
18.
Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial.
PLoS One;
15(5): e0233151, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469893
19.
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.
Lancet HIV;
6(4): e230-e239, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30885692
20.
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Clin Infect Dis;
46(11): 1769-81, 2008 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18433307